Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2015 | Side-effect of idelalisib and its use in chronic lymphocytic leukemia

Andrew Zelenetz • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia Bendamustine Idelalisib Rituximab

Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase III clinical trial of idelalisib plus bendamustine and rituximab in rlapsed/refractory chronic lymphocytic leukemia (CLL). Idelalisib is associated with colitis, pneumonitis, elevated transaminases, increased risk of febrile neutropenia, but these did not affect overall survival (OS).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.

More from Andrew Zelenetz

Novel lymphoma targets and agents
Andrew Zelenetz et al. • 8 Sep 2017
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma 16:39
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
Andrew Zelenetz et al. • 3 Oct 2015
m7-FLIPI identifies patients with early disease progression of FL after therapy 5:20
m7-FLIPI identifies patients with early disease progression of FL after therapy
Andrew Zelenetz • 4 Dec 2015
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL 4:51
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz • 4 Dec 2015

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals